The Ekso sale is complete and the board is streamlined to seven members. Monitor the annual meeting outcome for any dissident vote patterns, but no immediate catalyst is present.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Oct 19 $14.97entry
- T+1 · 28d ago +5.28%α +4.94% · $15.76
- T+5 · 22d ago −2.77%α −2.63% · $14.56
- T+20 · 16h ago −33.53%α −30.07% · $9.95
- T+60 · in 8w Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ChronoScale filed a DEFA14A supplement to its proxy statement removing Scott G. Davis as a director nominee following his resignation in connection with the sale of subsidiary Ekso Bionics. The filing also discloses $709,500 in cash severance to Davis and $243,750 to Jason Jones, both tied to the Ekso disposition. The annual meeting on November 6, 2026, will proceed with seven director nominees instead of eight.
Key Financial Metrics
Key Facts
- Scott G. Davis resigned from the board effective October 3, 2026, and is removed as a nominee for the 2026 annual meeting.
- The board now has seven nominees: Wes Cummins, Ying Cenly Chen, Richard Nottenburg, Ella Benson, Douglas Miller, William M. Clancy, and Andrew Schaap.
- Davis received 51,626 fully vested RSUs and a $709,500 cash release payment in connection with the Ekso sale.
- Jason Jones was terminated as COO of Ekso and receives $243,750 cash severance plus up to nine months of COBRA premiums.
- The annual meeting is scheduled for November 6, 2026, at 12:00 p.m. Eastern Time, held virtually.
- No votes will be counted for or against Davis; previously submitted proxies remain valid for the other seven nominees.
Financial Impact
Total cash severance of $953,250 ($709,500 to Davis + $243,750 to Jones) plus 51,626 RSUs fully vested at grant date value.
Risk Factors
- No material risk identified from this routine proxy supplement.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001493152-26-047435 |
| Document: 0001493152-26-047435-index-headers.html | 0001493152-26-047435 |
| Document: 0001493152-26-047435-index.html | 0001493152-26-047435 |
| Document: 0001493152-26-047435.txt | 0001493152-26-047435 |
Track record
17 reports on CHRN
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +28.76% at T+20 after the Oct 13, 2026 report. 3 of 4 went positive at some point.
Filters
- Oct 16, 20264w ago DEFA14A Neutral 3/10 Viewing Entry $14.97 to $15.76 Now $9.39 −37.27% ▲ +5.28% +4.94% vs SPY
- Oct 15, 20264w ago 8-K Mixed 6/10 No price data
- Oct 15, 20264w ago Press Release Mixed 6/10 Entry $15.08 to $14.97 Now $9.39 −37.73% ▼ −0.73% −1.15% vs SPY
- Oct 13, 20264w ago EFFECT Bearish 5/10 Entry $16.31 to $14.88 Now $9.39 +42.43% ▲ +8.77% +7.69% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $19.77 to $19.03 Now $9.39 −52.50% ▼ −3.74% −3.32% vs SPY
- Oct 6, 20265w ago S-3 Neutral 3/10 Entry $19.77 to $19.03 Now $9.39 −52.50% ▼ −3.74% −3.32% vs SPY
- Oct 2, 20266w ago 8-K Bullish 6/10 Entry $18.60 to $19.28 Now $9.39 −49.52% ▲ +3.66% +3.11% vs SPY
- Oct 1, 20266w ago Press Release Bullish 6/10 Entry $19.21 to $18.60 Now $9.39 −51.12% ▼ −3.18% −3.85% vs SPY
- Sep 25, 20267w ago DEFA14A Neutral 5/10 Entry $19.82 to $19.75 Now $9.39 −52.61% ▼ −0.33% −0.14% vs SPY
- Sep 25, 20267w ago DEF 14A Neutral 4/10 Entry $19.82 to $19.75 Now $9.39 −52.61% ▼ −0.33% −0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers